These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
183 related articles for article (PubMed ID: 24034562)
21. [Radiochemotherapy with gemcitabine and cisplatin in pancreatic cancer -- feasible and effective]. Wilkowski R; Thoma M; Heinemann V; Rau HG; Wagner A; Stoffregen C; Dühmke E Strahlenther Onkol; 2003 Feb; 179(2):78-86. PubMed ID: 12590317 [TBL] [Abstract][Full Text] [Related]
22. Treatment of patients with atypical meningiomas Simpson grade 4 and 5 with a carbon ion boost in combination with postoperative photon radiotherapy: the MARCIE trial. Combs SE; Edler L; Burkholder I; Rieken S; Habermehl D; Jäkel O; Haberer T; Unterberg A; Wick W; Debus J; Haselmann R BMC Cancer; 2010 Nov; 10():615. PubMed ID: 21062428 [TBL] [Abstract][Full Text] [Related]
23. [Locally advanced unresectable pancreatic cancer: Induction chemoradiotherapy followed by maintenance gemcitabine versus gemcitabine alone: Definitive results of the 2000-2001 FFCD/SFRO phase III trial]. Barhoumi M; Mornex F; Bonnetain F; Rougier P; Mariette C; Bouché O; Bosset JF; Aparicio T; Mineur L; Azzedine A; Hammel P; Butel J; Stremsdoerfer N; Maingon P; Bedenne L; Chauffert B Cancer Radiother; 2011 Jun; 15(3):182-91. PubMed ID: 21315644 [TBL] [Abstract][Full Text] [Related]
24. Clinical impact of radiotherapy for locally advanced pancreatic cancer. Sawaki A; Hoki N; Ito S; Matsumoto K; Mizuno N; Hara K; Takagi T; Kobayashi Y; Sawai Y; Kawai H; Tajika M; Nakamura T; Yamao K J Gastroenterol; 2009; 44(12):1209-14. PubMed ID: 19705054 [TBL] [Abstract][Full Text] [Related]
25. Full-dose gemcitabine with concurrent radiation therapy in patients with nonmetastatic pancreatic cancer: a multicenter phase II trial. Small W; Berlin J; Freedman GM; Lawrence T; Talamonti MS; Mulcahy MF; Chakravarthy AB; Konski AA; Zalupski MM; Philip PA; Kinsella TJ; Merchant NB; Hoffman JP; Benson AB; Nicol S; Xu RM; Gill JF; McGinn CJ J Clin Oncol; 2008 Feb; 26(6):942-7. PubMed ID: 18281668 [TBL] [Abstract][Full Text] [Related]
26. Combined radiochemotherapy of locally advanced unresectable pancreatic adenocarcinoma with mitomycin C plus 24-hour continuous infusional gemcitabine. Kornek GV; Pötter R; Selzer E; Schratter A; Ulrich-Pur H; Rogy M; Kraus G; Scheithauer W Int J Radiat Oncol Biol Phys; 2001 Mar; 49(3):665-71. PubMed ID: 11172947 [TBL] [Abstract][Full Text] [Related]
27. Randomized phase II study evaluating a carbon ion boost applied after combined radiochemotherapy with temozolomide versus a proton boost after radiochemotherapy with temozolomide in patients with primary glioblastoma: the CLEOPATRA trial. Combs SE; Kieser M; Rieken S; Habermehl D; Jäkel O; Haberer T; Nikoghosyan A; Haselmann R; Unterberg A; Wick W; Debus J BMC Cancer; 2010 Sep; 10():478. PubMed ID: 20819220 [TBL] [Abstract][Full Text] [Related]
28. Chemoradiation for ductal pancreatic carcinoma: principles of combining chemotherapy with radiation, definition of target volume and radiation dose. Wilkowski R; Thoma M; Weingandt H; Dühmke E; Heinemann V JOP; 2005 May; 6(3):216-30. PubMed ID: 15883472 [TBL] [Abstract][Full Text] [Related]
29. Prospective study of cetuximab and gemcitabine in combination with radiation therapy: feasibility and efficacy in locally advanced pancreatic head cancer. Fiore M; Trodella L; Valeri S; Borzomati D; Floreno B; Ippolito E; Trecca P; Trodella LE; D'Angelillo RM; Ramella S; Coppola R Radiat Oncol; 2015 Dec; 10():255. PubMed ID: 26670587 [TBL] [Abstract][Full Text] [Related]
30. Phase I-II trial of twice-weekly gemcitabine and concomitant irradiation in patients undergoing pancreaticoduodenectomy with extended lymphadenectomy for locally advanced pancreatic cancer. Joensuu TK; Kiviluoto T; Kärkkäinen P; Vento P; Kivisaari L; Tenhunen M; Westberg R; Elomaa I Int J Radiat Oncol Biol Phys; 2004 Oct; 60(2):444-52. PubMed ID: 15380578 [TBL] [Abstract][Full Text] [Related]
31. Phase II study of oral S-1 and concurrent radiotherapy in patients with unresectable locally advanced pancreatic cancer. Sudo K; Yamaguchi T; Ishihara T; Nakamura K; Hara T; Denda T; Tawada K; Imagumbai T; Araki H; Sakai M; Hatano K; Kawakami H; Uno T; Ito H; Yokosuka O Int J Radiat Oncol Biol Phys; 2011 May; 80(1):119-25. PubMed ID: 20605363 [TBL] [Abstract][Full Text] [Related]
32. A phase II study of fixed-dose rate gemcitabine plus low-dose cisplatin followed by consolidative chemoradiation for locally advanced pancreatic cancer. Ko AH; Quivey JM; Venook AP; Bergsland EK; Dito E; Schillinger B; Tempero MA Int J Radiat Oncol Biol Phys; 2007 Jul; 68(3):809-16. PubMed ID: 17363191 [TBL] [Abstract][Full Text] [Related]
33. Intensity-modulated radiotherapy (IMRT) and concurrent capecitabine for pancreatic cancer. Ben-Josef E; Shields AF; Vaishampayan U; Vaitkevicius V; El-Rayes BF; McDermott P; Burmeister J; Bossenberger T; Philip PA Int J Radiat Oncol Biol Phys; 2004 Jun; 59(2):454-9. PubMed ID: 15145162 [TBL] [Abstract][Full Text] [Related]
34. A phase I study of hypofractionated radiotherapy followed by systemic chemotherapy with full-dose gemcitabine in patients with unresectable locally advanced pancreatic cancer. Furuse J; Ishii H; Kawashima M; Nagase M; Nihei K; Nakachi K; Ogino T; Yoshino M Hepatogastroenterology; 2007; 54(77):1575-8. PubMed ID: 17708303 [TBL] [Abstract][Full Text] [Related]
35. Prognostic significance of carbohydrate antigen 19-9 in unresectable locally advanced pancreatic cancer treated with dose-escalated intensity modulated radiation therapy and concurrent full-dose gemcitabine: analysis of a prospective phase 1/2 dose escalation study. Vainshtein JM; Schipper M; Zalupski MM; Lawrence TS; Abrams R; Francis IR; Khan G; Leslie W; Ben-Josef E Int J Radiat Oncol Biol Phys; 2013 May; 86(1):96-101. PubMed ID: 23265573 [TBL] [Abstract][Full Text] [Related]
36. Maintenance chemotherapy after chemoradiation improves survival of patients with locally advanced pancreatic carcinoma: a retrospective analysis of prospectively recruited patients. Brunner TB; Tinkl D; Grabenbauer GG; Meyer T; Brueckl WM; Sauer R Strahlenther Onkol; 2006 Apr; 182(4):210-5. PubMed ID: 16622622 [TBL] [Abstract][Full Text] [Related]
37. Cost-effectiveness of modern radiotherapy techniques in locally advanced pancreatic cancer. Murphy JD; Chang DT; Abelson J; Daly ME; Yeung HN; Nelson LM; Koong AC Cancer; 2012 Feb; 118(4):1119-29. PubMed ID: 21773972 [TBL] [Abstract][Full Text] [Related]
38. Phase I study of concomitant gemcitabine and IMRT for patients with unresectable adenocarcinoma of the pancreatic head. Crane CH; Antolak JA; Rosen II; Forster KM; Evans DB; Janjan NA; Charnsangavej C; Pisters PW; Lenzi R; Papagikos MA; Wolff RA Int J Gastrointest Cancer; 2001; 30(3):123-32. PubMed ID: 12540024 [TBL] [Abstract][Full Text] [Related]
39. Evaluation of clinical factors and treatment results in patients with advanced pancreatic cancer. Brasiūnas V; Brasiūniene B; Juozaityte E; Barauskas G Medicina (Kaunas); 2004; 40(11):1074-80. PubMed ID: 15547308 [TBL] [Abstract][Full Text] [Related]
40. Feasibility and efficacy of combination therapy with preoperative full-dose gemcitabine, concurrent three-dimensional conformal radiation, surgery, and postoperative liver perfusion chemotherapy for T3-pancreatic cancer. Ohigashi H; Ishikawa O; Eguchi H; Takahashi H; Gotoh K; Yamada T; Yano M; Nakaizumi A; Uehara H; Tomita Y; Nishiyama K Ann Surg; 2009 Jul; 250(1):88-95. PubMed ID: 19561477 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]